Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study

被引：0
|
作者：
Samuel, L.
Miller, R.
Ross, P.
Arkenau, T. [1 ]
Antony, G. [2 ]
Veneris, J.
Rule, J. [2 ]
Starling, N. [3 ]
机构：
[1] Sarah Cannon Res Inst, London, England
[2] GlaxoSmithKline, London, England
[3] Royal Marsden, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
芬兰科学院;
关键词：
D O I：
10.1016/j.annonc.2023.04.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-164
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [31] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Pembrolizumab in microsatellite instability high (MSI-H)/ mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.
    Maio, Michele
    Ascierto, Paolo Antonio
    Manzyuk, Ludmila
    Motola-Kuba, Daniel
    Penel, Nicolas
    Cassier, Philippe A.
    Bariani, Giovanni
    De Jesus-Acosta, Ana
    Doi, Toshihiko
    Longo, Federico
    Miller, Wilson H.
    Oh, Do-Youn
    Gottfried, Maya
    Wang, Ruixue
    Jin, Fan
    Norwood, Kevin Glen
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [34] Interim analysis of the immune-related endpoints of the mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) and proficient/stable (MMRp/MSS) endometrial cancer cohorts from the GARNET study
    Hanker, L.
    Oaknin, A.
    Gilbert, L.
    Tinker, A., V
    Sabatier, R.
    Boni, V
    O'Malley, D.
    Ghamande, S.
    Duska, L.
    Ghatage, P.
    Sullivan, R. J.
    Moreno, V
    Veneris, J.
    Duan, T.
    Im, E.
    Pothuri, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 239 - 240
  • [35] Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    De Jesus-Acosta, A.
    Miller, W. H.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Yao, L.
    Gozman, A.
    Jin, F. J.
    Maio, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S797
  • [36] Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer (RC).
    Capdevila, Jaume
    O'Donnell, Sean
    Borkowska, Katarzyna
    Frampton, James
    Betts, Marissa
    Maierhofer, Courtney
    Kalilani, Linda
    Garside, Jamie
    Wang, Huifen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 303 - 303
  • [37] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
    Guo, W.
    Bi, F.
    Dong, J.
    Jin, C.
    Niu, Z.
    Wang, Y.
    Sun, M.
    Wang, T.
    Yu, D.
    He, Y.
    Zhang, R.
    Yin, X.
    Feng, W.
    Zhang, M.
    Li, L.
    Zhang, B.
    Kang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1511 - S1511
  • [39] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [40] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study
    Vogel, A.
    Hanker, L.
    Andre, T.
    Berton, D.
    Curigliano, G.
    Ellard, S. L.
    Trigo, J.
    Arkenau, H. -T
    Abdeddaim, C.
    Moreno, V
    Guo, W.
    Im, E.
    Starling, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 82 - 82
12345